Duthie T, Trueman P, Chancellor J, Diez L
Global Health Outcomes, Glaxo Wellcome R&D, Greenford, Middlesex, UK.
Health Policy. 1999 Jan;46(2):143-57. doi: 10.1016/s0168-8510(98)00057-8.
The purpose of this phased research project is to better understand the role of health economic arguments in the decision making process of healthcare providers and purchasers in the United Kingdom. Phase I of the research was directed at General Practitioners (GPs); in phase II we broadened the scope of the research to include different agents who influence resource allocation and the wider health care environment. The objective of phase II was to determine the relevance and appeal of diverse health economic measures to different decision makers. This phase of qualitative research involved 34 decision makers in 17 duo interviews. The study has provided a rich source of qualitative evidence on the role of health economics in decision making. The main conclusions to emerge are; different individuals seek different outcomes; health economic studies should report actionable conclusions; and any cost savings must be applicable. To succeed, economists need to demonstrate a better understanding of the contracting and budgetary processes of the National Health Service. Opinions of the value of health economic evaluations varied widely, however most respondents believed it would become increasingly influential in the prioritisation process in the National Health Service of the future.
这个分阶段研究项目的目的是更深入地了解健康经济论据在英国医疗服务提供者和购买者决策过程中的作用。研究的第一阶段针对全科医生（GPs）；在第二阶段，我们扩大了研究范围，将影响资源分配的不同主体以及更广泛的医疗环境纳入其中。第二阶段的目标是确定各种健康经济措施对不同决策者的相关性和吸引力。这一定性研究阶段涉及17次双人访谈中的34位决策者。该研究为健康经济学在决策中的作用提供了丰富的定性证据来源。得出的主要结论是：不同的个体追求不同的结果；健康经济研究应报告可付诸行动的结论；任何成本节约都必须切实可行。为了取得成功，经济学家需要更好地理解国民医疗服务体系的合同签订和预算流程。对健康经济评估价值的看法差异很大，然而，大多数受访者认为它在未来国民医疗服务体系的优先排序过程中将变得越来越有影响力。
